Acquired from current majority shareholder, Custos Vermögensverwaltungs GmbH and minority shareholders, the acquisition has built upon Lubrizol’s expertise in precision thermoplastic extrusion and product development.
The acquisition has expanded Lubrizol’s product design, development and manufacturing expertise and provides access to proprietary catheter and balloon technologies, according to a statement.
With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. The company has developed the first commercial drug-coated balloon, the Paccocath™ catheter.
Currently, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. It also offers private label manufacturing of proprietary catheters and balloons, along with original equipment manufacturing services.
Headquartered in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices worldwide. For more information, contact www.lubrizol.com.
-- BERNAMA
No comments:
Post a Comment